503A Peptide Compounding Pharmacy

Get Updates on Peptide Availability

Massey Drugs is preparing to offer BPC-157, TB-500, KPV, and MOTS-c. Sign up to receive updates about availability, pricing, and ordering information as these preparations become available. Prescribers will be directed to sign up for our portal. 

Peptide Availability at Massey Drugs 503A Compounding Pharmacy

Following the recent announcement from the U.S. Department of Health and Human Services (HHS), a new pathway is opening for qualified 503A compounding pharmacies to prepare six peptides: BPC-157, TB-500, KPV, MOTS-c, Epitalon, and Semax. This interim policy represents an important step toward expanding patient access to these peptides through regulated, state-licensed compounding pharmacies.

As an NABP-accredited 503A peptide compounding pharmacy, Massey Drugs is actively working to bring these therapies to prescribers and their patients as quickly as possible. Our anticipated initial offerings include BPC-157, TB-500, KPV, and MOTS-c. Our team is completing the necessary preparations to meet applicable federal and state requirements while maintaining the quality and safety standards that guide our compounding practices.

The infographic below outlines the steps Massey Drugs is taking to bring these prescription peptides to patients.

Massey Drugs 503A peptide compounding pharmacy

Peptides We Are Preparing to Offer

Massey Drugs is preparing to offer four peptides under the new HHS interim enforcement-discretion policy. Each peptide has unique biological properties and is being investigated for potential therapeutic applications. Our initial focus includes:

BPC-157

BPC-157
Research Focus: Tissue Repair and Recovery

BPC-157 (Body Protection Compound-157) is a synthetic peptide studied for its potential involvement in tissue repair, inflammation, and recovery processes. Preclinical research has explored its effects on tendons, ligaments, muscles, and gastrointestinal tissues. However, human clinical evidence remains limited, and its safety and effectiveness for these uses have not been established.

TB-500

TB-500
Research Focus: Tissue Repair and Cellular Function

TB-500 is a synthetic peptide associated with research involving tissue repair, cellular migration, and recovery. Much of the scientific interest relates to the biological functions of thymosin beta-4. However, findings involving thymosin beta-4 should not automatically be attributed to TB-500, and clinical evidence supporting TB-500 in humans remains limited.

KPV

KPV
Research Focus: Inflammation and Skin Health

KPV is a tripeptide consisting of three amino acids: lysine, proline, and valine. Researchers have investigated its potential anti-inflammatory properties, particularly in relation to skin and gastrointestinal inflammation. Most available findings are preclinical, and its clinical effectiveness in humans has not been established.

MOTS-c

MOTS-c
Research Focus: Metabolic Health and Cellular Energy

MOTS-c is a mitochondria-derived peptide being investigated for its potential role in cellular metabolism, insulin sensitivity, and metabolic regulation. Early research has examined its relationship to energy utilization and metabolic function. Additional human clinical research is needed to determine its safety and potential therapeutic applications.

Sermorelin – Available Now!
Research Focus: Growth Hormone Stimulation and Healthy Aging

Sermorelin is a synthetic peptide that stimulates the pituitary gland to release growth hormone (GH). As an analog of growth hormone-releasing hormone (GHRH), it has been studied for its role in supporting the body’s natural growth hormone production, which is involved in metabolism, muscle maintenance, and tissue repair. Sermorelin has been investigated for growth hormone deficiency and age-related changes in growth hormone secretion, although evidence supporting its use for anti-aging and general wellness remains limited.

These peptides are investigational and are not FDA-approved treatments. Research findings do not establish clinical effectiveness or safety for any particular condition.

Why Choose Massey Drugs for Peptide Compounding?

NABP Accredited Compounding Pharmacy

As an NABP-compounding accredited 503A compounding pharmacy, Massey Drugs is committed to providing high-quality, patient-specific compounded medications. Our pharmacy follows applicable USP compounding standards and maintains established quality-control procedures for sterile and nonsterile preparations.

As we prepare to introduce peptide compounding, our priorities include:

  • Qualified Ingredients: Sourcing peptide APIs that meet applicable federal quality requirements.
  • Quality Testing: Establishing appropriate testing procedures to verify compounded product quality.
  • Regulatory Compliance: Following applicable federal and state requirements.
  • Prescriber Support: Providing clear information about availability, formulations, and prescription requirements.

Peptide Availability and Pricing

When will compounded peptides be available from Massey Drugs?

We are actively working toward making BPC-157, TB-500, KPV, and MOTS-c available. Our team is qualifying ingredient suppliers, preparing formulations, and establishing the necessary testing and quality-control procedures.

An official availability date has not yet been established. We will share updates as we complete the requirements necessary to begin dispensing.

How much will compounded peptides cost?

Pricing is currently being determined. Final costs will depend on qualified ingredient sourcing, formulation requirements, and quality testing. Clinic and patient pricing will be announced once these details are finalized.

States We Serve

States where Massey Drugs ships compounded medications.

Massey Drugs is licensed to dispense and ship prescription medications to patients in 16 states, making our compounded medications accessible to patients and prescribers across a growing service area.

States We Serve: Alabama, Connecticut, Florida, Georgia, Illinois, Indiana, Kentucky, Louisiana, Mississippi, New York, North Carolina, Ohio, Pennsylvania, South Carolina, Tennessee, and Texas.

Peptide availability is subject to applicable state regulations.

Frequently Asked Questions About Peptide Compounding

What changed with the new HHS peptide policy?

HHS announced an interim enforcement-discretion policy covering certain forms and routes of six peptides: BPC-157, TB-500, KPV, MOTS-c, Epitalon and Semax. HHS states that it does not intend to take enforcement action against state-licensed 503A pharmacies when every condition in the policy is met.

No. These peptides have not been approved by FDA as safe and effective treatments. The policy provides a temporary, conditional pathway while FDA completes formal rulemaking to determine whether any of them should be added to the 503A Bulks List.

Massey’s anticipated initial focus is BPC-157, TB-500, KPV and MOTS-c. Final availability will depend on federal requirements, individual state laws, qualified ingredient sourcing and completion of Massey’s quality and reporting procedures.

Not yet. Massey is not currently accepting prescriptions for BPC-157, TB-500, KPV, or MOTS-c. We will notify interested prescribers and patients when ordering opens and provide instructions for submitting prescriptions.

A launch date has not been established. Before accepting prescriptions, Massey must confirm compliant ingredient sourcing and testing, develop and evaluate its preparations, establish required labeling and reporting procedures, and determine which states will permit dispensing.

Not yet. Pricing will depend partly on qualified ingredient sourcing, testing, dosage form and preparation requirements. Massey will announce pricing before it begins accepting prescriptions.

Not necessarily. The HHS policy establishes a federal enforcement position, but it does not override state pharmacy or medical-practice laws. Massey will identify eligible states after completing its state-by-state review.

Yes. The policy requires a valid prescription for an identified individual patient. It does not authorize over-the-counter sales or the sale of peptides for general office stock.

No. Massey recommends waiting until availability and ordering instructions are announced. This will help ensure that the prescribed peptide, chemical form, dosage form, route and patient’s state are eligible.

Transfer eligibility will depend on the prescription, state law and whether Massey offers the prescribed preparation. Massey will provide transfer guidance after it begins accepting prescriptions.

Coverage is expected to be limited because compounded peptide preparations are not FDA-approved drugs. Massey will provide available payment and pricing information before launch, but patients should not assume their insurance will cover them.

The policy specifies the following:

  • BPC-157 acetate: subcutaneous, intramuscular, oral or topical
  • TB-500 acetate: subcutaneous or intramuscular
  • MOTS-c acetate: subcutaneous or intramuscular
  • KPV acetate: topical or oral
  • Epitalon acetate: subcutaneous or intramuscular in intermittent courses
  • Semax free base: intranasal

Massey has not yet announced which eligible dosage forms it will offer.

Strengths have not been finalized. They will be announced after formulation, quality and operational reviews are complete.

Massey plans to provide clear ordering information when prescriptions are accepted. Any prescription resources will reflect the preparations, routes and states Massey has confirmed it can serve.

No. The HHS policy applies only to preparations containing one covered peptide as the active ingredient. Peptide blends are not included in the policy’s enforcement discretion.

The policy requires a valid patient-specific prescription but does not establish approved indications for these peptides. Prescribers remain responsible for determining whether a prescription is medically appropriate and complies with the laws and professional standards of their state.

The HHS policy does not establish one universal informed-consent form. Because these are compounded, non-FDA-approved preparations with limited clinical evidence, prescribers should consider documenting a discussion of their unapproved status, potential risks, expected benefits, alternatives and uncertainties. State-specific requirements may also apply.

Massey will provide applicable storage, administration, handling and reporting information with the dispensed preparation. Clinical monitoring decisions remain the responsibility of the treating prescriber.

The policy requires serious adverse events and product-quality problems to be reported to FDA and applicable states. Massey’s final labeling will explain how patients and prescribers should report concerns to the pharmacy. Serious adverse events may also require submission through FDA MedWatch.

The policy requires the original API manufacturer to be FDA-registered and compliant with applicable manufacturing requirements. The manufacturer’s identity and physical location must be documented, and the API must be accompanied by a qualifying certificate of analysis. Massey will only move forward when it can verify that its source meets the applicable requirements.

The policy requires extensive characterization and testing addressing identity, purity, potency, impurities and applicable microbial, endotoxin, residual-solvent, elemental-impurity and other quality attributes. Exact requirements differ according to the peptide and intended route.

The HHS policy requires patient-specific prescriptions, qualified ingredient sourcing, detailed certificates of analysis, specified routes, quality controls, required labeling and adverse-event reporting. Products sold as “research use only” may not provide the same prescription oversight, sourcing verification, testing, traceability or pharmacist access.

Peptide active pharmaceutical ingredients (APIs) must meet applicable federal quality and sourcing requirements. Under the recent HHS enforcement-discretion policy, these requirements include sourcing from appropriately registered manufacturers, verifying peptide identity and purity, and reviewing analytical testing documentation.

Massey Drugs is taking a comprehensive approach to supplier qualification and quality verification as we prepare to offer these therapies.

Regulatory Notice: Peptide formulations referenced on this page are discussed for informational purposes only. Compounded medications may only be prepared when permitted under applicable federal and state compounding regulations governing bulk drug substances.